ライフサイエンスコーパス: noncarrier

1 oncarriers, respectively, compared with PiB- noncarriers).

2 fined by APOE genotype (epsilon4 carriers vs noncarriers).

3 eeping infants (60 epsilon4 carriers and 102 noncarriers).

4 pe, and 284 individuals without the variant (noncarriers).

5 al, short-term, or long-term carrier or as a noncarrier.

6 spectively, for an 85-year-old APOE epsilon4 noncarrier.

7 erm carriers; the remaining 530 (80.8%) were noncarriers.

8 Pi*ZZ variant, but these were higher than in noncarriers.

9 tion cohort of 446 V617F carriers vs 169 021 noncarriers.

10 verely affected in mutation carriers than in noncarriers.

11 n carriers and 5.1% (95% CI, 4.5 to 5.7) for noncarriers.

12 activity and nigrostriatal function than PD noncarriers.

13 ntrol of the index cancer similar to that of noncarriers.

14 370S and 56 severe mainly p.L444P) and 2,641 noncarriers.

15 wer risk of coronary artery disease than did noncarriers.

16 , were similar between mutation carriers and noncarriers.

17 ss (P=4x10(-)(14)) in carriers compared with noncarriers.

18 0.001) and death (HR = 1.85; p = 0.002) than noncarriers.

19 01 [30.6%]; P = .008) compared with the 1498 noncarriers.

20 as stronger in APOEepsilon4 carriers than in noncarriers.

21 mong carriers of the E40K variant than among noncarriers.

22 ly to have coronary artery disease than were noncarriers.

23 ignificantly greater median amyloid PET than noncarriers.

24 cognitively unimpaired mutation carriers and noncarriers.

25 for APOE epsilon4 carriers and 64 years for noncarriers.

26 cosahexaenoic acid (DHA) supplement than are noncarriers.

27 earlier onset age despite being leaner than noncarriers.

28 bjects with the Pi*MZ genotype compared with noncarriers.

29 ormal apolipoprotein E4 (APOE4) carriers and noncarriers.

30 2.34; 95% CI, 1.05-5.22) in comparison with noncarriers.

31 arkinson pathology in TREM2 R47H carriers vs noncarriers.

32 diovascular or other health benefits than do noncarriers.

33 les have greater risk of kidney disease than noncarriers.

34 was performed in 88 p.T224M carriers and 54 noncarriers.

35 respectively, and 56 (49-66) nmol/ml/min for noncarriers.

36 s (hereafter referred to as carriers) and 23 noncarriers.

37 epsilon4 allele and the other involving 1331 noncarriers.

38 in APOE epsilon4 allele carriers but not in noncarriers.

39 line in eGFR, and albuminuria, compared with noncarriers.

40 ALT case incidence between HLA carriers and noncarriers.

41 erozygotes who carry 2 PARKIN mutations with noncarriers.

42 RD, 6.1% [95% CI, 1.4%-13.0%]) compared with noncarriers.

43 exhibited higher PIB retention compared with noncarriers.

44 ngest effect being observed in APOE-epsilon4 noncarriers.

45 unger (P = .004) at time of examination than noncarriers.

46 polipoprotein E (APOE) epsilon4 carriers and noncarriers.

47 tively, and 37.9 (30.5-43.7) nmol/ml/min for noncarriers.

48 inical feature between mutation carriers and noncarriers.

49 om onset compared with asymptomatic mutation noncarriers.

50 nced episodic memory performance relative to noncarriers.

51 e in patients with rare variants of MC4R and noncarriers.

52 riers were compared with sex- and age-paired noncarriers.

53 y composition between S. aureus carriers and noncarriers.

54 ain amyloid burden relative to APOE epsilon4 noncarriers.

55 the clinical characteristics of carriers and noncarriers.

56 tastases at diagnosis (P = .005) than PCa in noncarriers.

57 syndrome, heterozygous carriers, and healthy noncarriers.

58 had a larger hippocampal volume relative to noncarriers.

59 was significantly higher in carriers than in noncarriers.

60 outcomes did not differ by treatment type in noncarriers.

61 ection (SSI) following colorectal surgery as noncarriers.

62 urgery is higher in ESBL-PE carriers than in noncarriers.

63 occur at higher frequencies in carriers than noncarriers.

64 cers have been observed in both carriers and noncarriers.

65 rt and separately for the APOE4 carriers and noncarriers.

66 greater need for organ support compared with noncarriers.

67 % of heterozygous carriers and 4% of healthy noncarriers.

68 haptoglobin (Hp) 1-1 genotype compared with noncarriers.

69 s and to provide appropriate reassurances to noncarriers.

70 h hemoglobin C trait, and 234 of 8927 (2.6%) noncarriers.

71 2% is explained by HbA1c levels among Hp 1-1 noncarriers.

72 s with SCT and 4.0 per 1000 person-years for noncarriers.

73 egulation in serum samples from carriers and noncarriers.

74 T had 366 prediagnosis mutation carriers and noncarriers.

75 included 640 APOB R3527Q carriers and 4,683 noncarriers.

76 ores at autopsy, even among APOE varepsilon4 noncarriers.

77 ated with smaller hippocampal volume than in noncarriers.

78 rriers] and 14,727 participants without SCT [noncarriers]).

79 ratios (mean [SD]: carriers, 0.32 [0.06] and noncarriers, 0.21 [0.03]; P < .001), as well as less mem

80 on carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P < .001).

81 ity, carriers had a somewhat higher BMI than noncarriers (1.44 +/- 0.07 standard deviation scores [SD

82 to <30, and >/=30 ng/mL) and risk genotype (noncarrier, 1 risk allele, or 2 risk alleles).

83 een BRCA1 carriers (10-year risk = 7.3%) and noncarriers (10-year risk = 7.9%).

84 63 years) was more frequent in carriers than noncarriers (10/33 vs. 3/37, p = .029), as well as the p

85 curred in 55/220 carriers (24.8%) and 49/440 noncarriers (11.1%, P < .001).

86 terminal pro-brain natriuretic peptide, than noncarriers (1194 participants), although carriers had a

87 1247 SCT carriers [19.2%] vs 1994 of 14,722 noncarriers [13.5%]) had CKD, 1298 (140 of 675 SCT carri

88 of 675 SCT carriers [20.7%] vs 1158 of 8481 noncarriers [13.7%]) experienced incident CKD, 1719 (150

89 s (mean [SD]: carriers, 18.8 [5.1] pg/mL and noncarriers, 13.1 [3.2] pg/mL; P < .001) and Abeta1-42:A

90 tality between carriers (41 deaths, 33%) and noncarriers (1382 deaths, 37%; age- and sex-stratified h

91 the TM6SF2 rs58542926-T allele compared with noncarriers: 15.7 (+/- 10.5) versus 10.8 (+/- 5.7) ng/L

92 h erosions of the hands and feet were 48% of noncarriers (150/314) of valine at position 11, 61% of h

93 of 665 SCT carriers [22.6%] vs 1569 of 8249 noncarriers [19.0%]) experienced decline in eGFR, and 13

94 of 485 SCT carriers [31.8%] vs 1168 of 5947 noncarriers [19.6%]) had albuminuria during the study pe

95 Three of 12 noncarriers (25%) from the PSEN1 A79V family are potenti

96 /116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2

97 d ratio, 1.16 [95% CI, 1.03-1.31], P = .01) (noncarriers: 319 deaths in 1398 patients over 17,196 per

98 iant carriers (124 participants [3%]) versus noncarriers (3732 participants).

99 ant carriers were significantly younger than noncarriers (41 vs. 50 years, P < 0.05).

100 enetic status was associated with lower OEF (noncarriers, 41.1% 6 5.8; one E4 allele, 40.1% 6 4.9; tw

101 Twenty-eight noncarriers (42%; age, 10 +/- 4 years) served as control

102 te a similar mean pulmonary artery pressure (noncarriers 54+/-15 versus mutation carriers 55+/-9 mm H

103 nosis was younger for mutation carriers than noncarriers (54.3 v 62.3 years; P < .01), with five carr

104 as earlier in GBA1 mutation carriers than in noncarriers (63.5 vs 68.9 years; P < .001), with higher

105 apy (OR, 1.14 [95% CI, 1.01-1.30], P = .04) (noncarriers: 78% [439/561 patients] with moderate or goo

106 rticipated in multiple surveys: 71% remained noncarriers, 8% cleared carriage, 15% remained carriers,

107 icipants (28 Hp 1-1 carriers [12.5%] and 196 noncarriers [87.5%]) from the Israel Diabetes and Cognit

108 (SD) age was 40.06 (8.92) years; of the 156 noncarriers, 87 (55.7%) were women, and the mean (SD) ag

109 infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7).

110 rt disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7).

111 ear CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93%

112 ad a lower level of non-HDL cholesterol than noncarriers, a difference of 15.3 mg per deciliter (0.40

113 74% lower in del2.5 carriers than in 101 851 noncarriers, a difference of 2.48 mmol/L (96 mg/dL; P=8.

114 tality between V122I TTR allele carriers and noncarriers, a finding that contrasts with prior observa

115 the rs3746266 G allele had a lower BMI than noncarriers (AA genotype) (sample 1, P = .001; sample 2,

116 Relative to noncarriers, ADRA2b deletion carriers showed higher leve

117 cted family members (referred to as familial noncarriers; age range, 1-46 years; mean age, 11.7 years

118 e assessed in 18 PSEN1 E280A carriers and 19 noncarriers aged 9 to 17 years from a Colombian kindred

119 r the right precuneus were -0.590 [0.50] for noncarriers and -0.087 [0.38] for carriers; P < .005 unc

120 ] parameter estimates were 0.038 [0.070] for noncarriers and 0.190 [0.057] for carriers), as well as

121 A total of 100 APOE4 noncarriers and 100 APOE4 carriers had the primary clini

122 ulations segregating p.Y111C and p.R518X (74 noncarriers and 110 KCNQ1 mutation carriers, whereof 13

123 African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the iden

124 HR of 1.17 (95% CI: 0.85, 1.61) in the ApoE4 noncarriers and an HR of 0.93 (95% CI: 0.50, 1.72) in th

125 HR of 1.04 (95% CI: 0.89, 1.22) in the ApoE4 noncarriers and an HR of 0.95 (95% CI: 0.73, 1.25) in th

126 lower systolic BP and higher heart rate than noncarriers and heterozygote carriers; they also had sig

127 ermediate phenotype, between that of healthy noncarriers and patients with Gitelman syndrome.

128 icker corpora callosa compared with familial noncarriers and population control participants (16%; P

129 most salient findings compared with familial noncarriers and population control participants were rec

130 zed based on their genotype (carriers versus noncarriers) and phenotype (extensive, intermediate, and

131 cluding 81 heterozygous carriers, 82 healthy noncarriers, and 79 patients with Gitelman syndrome.

132 rying the ABCG2 Y581S polymorphism (Y/S) and noncarrier animals (Y/Y).

133 ts, representing both S. aureus carriers and noncarriers at three nasal sites (anterior naris, middle

134 kely that carriers can be discriminated from noncarriers based solely on phenotypical characteristics

135 beta = 0.18, 95%CI: -0.41, 0.78) compared to noncarriers (beta = 1.25, 95%CI: 0.58, 1.93).

136 a responders to the DHA supplement than were noncarriers but only in the high-BMI group.

137 g these rare variants differ clinically from noncarriers by an earlier age at symptom onset, higher p

138 jectories were compared between carriers and noncarriers by testing the "age by genetic status" inter

139 Compared with noncarriers, carriers of 4 risk alleles of rs10741657 an

140 Compared with noncarriers, carriers of PTV at CETP displayed higher hi

141 Compared with noncarriers, carriers of PTV at CETP had higher high-den

142 ln carriers vs 874.0 and 946.7 microg/mL for noncarrier cases and controls, respectively.

143 eu carriers vs 302.4 and 283.0 microg/mL for noncarrier cases and controls, respectively.

144 eu131Arg carriers vs 27.2 and 30.4 mug/mL in noncarrier cases and controls, respectively; both P < .0

145 (10.7 microg/mL vs 6.6 and 6.1 microg/mL in noncarrier cases and controls, respectively; P < .001).

146 f 88 mutation carriers and 82 (51.2%) of 160 noncarriers chose bilateral mastectomy (P < .001).

147 Compared with noncarriers, cognitively unimpaired mutation carriers ha

148 for negative stimuli compared with deletion noncarriers, consistent with prior studies.

149 a DHA-rich supplement in APOE4 carriers and noncarriers consuming a high-saturated fat diet (HSF die

150 d with carriers, stimulated whole blood from noncarriers contained on average 60% more interferon gam

151 x best characterized EEV-related activity in noncarriers, contributions of an additional VMPFC pathwa

152 d characteristics compared with the familial noncarrier control group.

153 115 (38.5%) first-degree relatives who were noncarrier controls.

154 vated in ApoE4 allele carriers compared with noncarrier controls.

155 EN1 E280A mutation carriers and 257 mutation noncarriers (December 2013-February 2017).

156 er BP response to hydrochlorothiazide versus noncarriers (Delta systolic BP/Delta diastolic BP: -12.3

157 Tc prolongation in mutation carriers than in noncarriers, demonstrating synergistic effects of innate

158 is variant had higher uromodulin levels than noncarriers did (geometric means 10.24, 14.05, and 17.67

159 lier diagnosis, as well as using exclusively noncarrier donors and achieving complete donor chimerism

160 ions have decreased fat intake compared with noncarriers (DRD4 7+ mean, 29.03% of calories derived fr

161 eased fat intake compared with girls who are noncarriers (DRD4 7+ mean, 33.95% of calories derived fr

162 ity, but IQ scores were 26 points lower than noncarrier family members on average.

163 ions of a family with late-onset ADAD and 12 noncarrier family members were followed up at the Knight

164 n a novel cohort of adult carriers and their noncarrier family members.

165 rs having a younger age at cancer onset than noncarriers for FAMMM-related cancers (as expected) as w

166 n = 1223) vs the remaining controls who were noncarriers for V617F (n = 252 140).

167 senilin 1 (PSEN1)E280A mutation carriers and noncarriers from the world's largest known autosomal dom

168 among PSEN1 mutation carriers, compared with noncarriers, from approximately 25 years and older, whic

169 By contrast, noncarriers (GG) showed no significant differences in MI

170 white matter MWF and GMV in the carrier and noncarrier groups and characterized their associations w

171 The carrier and noncarrier groups were matched for age, gestational dura

172 re compared in the APOE epsilon4 carrier and noncarrier groups.

173 of subjects with the Pi*MZ genotype vs 4% of noncarriers had LSMs of 7.1 kPa or more (adjusted odds r

174 l sclerosis (61.5%), whereas only 145 of 612 noncarriers had positive family history (23.7%; p<.00000

175 th patients who received mastectomy, both in noncarriers (hazard ratio [HR] = 0.95, confidence interv

176 =5.2x10(-)5) in contrast to no difference in noncarriers (hazard ratio, 0.96; 95% confidence interval

177 riers was two to three times higher than for noncarriers (hazard ratios, 3.31 [95% CI, 2.41 to 4.55;

178 Compared with healthy noncarriers, heterozygous carriers showed significantly

179 e heterozygous (ID genotype), and 7 who were noncarriers (II genotype) for assessment of adipose hist

180 ognitive decline among CLU risk carriers and noncarriers in individuals who remained cognitively norm

181 in E (APOE) epsilon4 allele carriers than in noncarriers in participants (mean [SD], 1.66 [0.41] vs 1

182 and 6-month survival advantage compared with noncarriers in patients with resected disease, with an a

183 iers had lower MWF and GMV measurements than noncarriers in precuneus, posterior/middle cingulate, la

184 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.0

185 of decline in memory performance relative to noncarriers in the presymptomatic stages of disease prog

186 ight-independent resolution of diabetes than noncarriers, indicating a role for MC4Rs in the effects

187 ower in APOE epsilon4 carriers compared with noncarriers irrespective of diagnostic group (cohort A).

188 iers was 80.9% (95% CI, 75.4% to 86.4%); for noncarriers, it was 82.2% (95% CI, 80.5% to 83.7%).

189 ar intracerebral hemorrhage) and 17 mutation noncarriers (M(-) ).

190 riers of ALG9 loss-of-function mutations and noncarrier matched controls in a large exome-sequenced p

191 4.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] age, 67.1 [11.8] years; 54.9% fem

192 dentified variants (n = 177) and age-matched noncarriers (n = 157).

193 C9ORF72 mutation (n = 10) were compared with noncarriers (n = 19) and a healthy control group (n = 35

194 s (n = 98) had a 1.81-kg/m(2) lower BMI than noncarriers (n = 226; P < .0001).

195 We identified carriers (N = 20) and matched noncarriers (N = 25) for this allele in the population-b

196 In noncarriers (N = 5820), as well as in BRCA1 (N = 191) an

197 controls (n=6), mutation carriers (n=5), and noncarriers (n=11).

198 Compared with noncarriers (n=389), children with genomic disorders (n=

199 c mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12).

200 ntly different between mutation carriers and noncarriers (no left ventricular remodeling or fibrosis,

201 GBA noncarrier non-PD spouse control participants were recru

202 on was 40% lower than the risk among 110,472 noncarriers (odds ratio, 0.60; 95% confidence interval,

203 re reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, resp

204 x 10-6), and tended to be lower than that of noncarriers of normal weight (-0.29 +/- 0.003; P = 0.05)

205 of carriers of normal weight was similar to noncarriers of normal weight, whereas among individuals

206 cerols (TAGs) between carriers compared with noncarriers of PNPLA3(I148M) gene variant display defici

207 rriers of the PPARG G allele (rs1801282) and noncarriers of PPARGC1A A allele (rs8192678) had 21 and

208 Differences between carriers and noncarriers of rare variants in age at onset of symptoms

209 ment were also compared between carriers and noncarriers of specified MHC variants.

210 Carriers compared with noncarriers of the ADRA2B deletion variant exhibited a s

211 fMRI results indicated that, whereas noncarriers of the ADRA2B deletion variant showed increa

212 Noncarriers of the APOE epsilon4 allele with severe CAA

213 es were repeated separately for carriers and noncarriers of the APOE epsilon4 allele.

214 In noncarriers of the CR1 risk allele, APOE epsilon4 indivi

215 mporal lobe cortices in healthy carriers and noncarriers of the KIBRA T-allele (rs17070145).

216 In our data, carriers and noncarriers of the p.E508K mutation with type 2 diabetes

217 mpare the frequency of AF among carriers and noncarriers of these rare variants.

218 TS: Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 yea

219 They performed better than noncarriers on the Mini-Mental State Examination (P = .0

220 silon4 carriers had greater progression than noncarriers on the partner (1.10, SE=0.44, P<.012) and s

221 ate analyses, carriers performed better than noncarriers on the UPDRS-III (P = .02) and on tests of a

222 g potential benefits of RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin o

223 -PE occurred in 7.2% of carriers and 1.6% of noncarriers (OR, 4.23; 95% CI, 1.70-10.56).

224 carriers but in only two neonatally screened noncarriers (P < .001); six patient cases were identifie

225 They had lower serum lipid levels than noncarriers (P < 0.05), had more-severe steatosis, necro

226 k for PD was higher in patients with GD than noncarriers (P = .008, log-rank test) and in heterozygot

227 08, log-rank test) and in heterozygotes than noncarriers (P = .03, log-rank test), but it did not rea

228 or carriers was 28.2 (5.5) vs 29.3 (5.3) for noncarriers (P = .19).

229 s 45.3 years (11.2) vs 47.5 years (11.5) for noncarriers (P = .49) and the mean (SD) BMI for carriers

230 in Mini-Mental State Exam scores compared to noncarriers (p = 0.0009).

231 0.0007) versus a 0.009-mL decrease in Hp 1-1 noncarriers (P = 0.047), after adjusting for total intra

232 rsion was similar between APOE4 carriers and noncarriers (p = 0.321), indicating that the non-Cp copp

233 as no different between variant carriers and noncarriers (p = 0.99).

234 t had higher NFATC2 expression compared with noncarriers (P = 1.1 x 10(-3) and 0.03, respectively).

235 n the carriers were 39% lower than levels in noncarriers (P<1x10(-20)), and circulating levels of APO

236 s disease had poorer cognitive function than noncarriers (P=0.003).

237 rface expression of the LDL receptor than in noncarriers (P=0.0086).

238 ter (0.31 mmol per liter) lower than that in noncarriers (P=0.04).

239 C3 in carriers were 46% lower than levels in noncarriers (P=8x10(-10)).

240 gate carrier, and absent from the unaffected noncarrier parent in 1 DBA family.

241 als with de novo 16p11.2 deletions and their noncarrier parents and siblings from the Simons Variatio

242 Results from 31 carrier and 38 noncarrier parents from 40 families were compared with c

243 ent anticipation in which rare variants from noncarrier parents may attenuate constitutive resistance

244 carriers (heterozygotes, n = 694), and among noncarriers (parents of non-PD, non-GD control participa

245 6 versus 116.1 to 125.7 mg/dL) compared with noncarrier participants.

246 In healthy S aureus carriers and noncarriers, peripheral blood T cells elaborated TH2 cyt

247 FI levels correlated with C3b degradation in noncarriers (R2 = 0.35 and R2 = 0.31, respectively; both

248 lleles received ticagrelor or prasugrel, and noncarriers received clopidogrel.

249 or prasugrel (genotyping with prasugrel) and noncarriers receiving clopidogrel.

250 by 26.3 points between proband carriers and noncarrier relatives and a lower mean FSIQ score (16.2-1

251 ers (80 symptomatic and 38 asymptomatic), 58 noncarrier relatives from 40 families, and 200 healthy d

252 letion on clinical traits by comparison with noncarrier relatives.

253 tures that discriminate between carriers and noncarriers remain unclear.

254 I, 0.9-2.8, for PiB+ APOE4 carriers and PiB+ noncarriers, respectively, compared with PiB- noncarrier

255 among heterozygotes, and 0.7% and 2.1% among noncarriers, respectively.

256 were compared between mutation carriers and noncarriers.RESULTS Of 86 patients with SNs, 25 (29%) ha

257 ECG data from mutation carriers and noncarriers revealed that the K422T mutation per se had

258 e carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT

259 No such deficits were observed in noncarrier spouses.

260 study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) wit

261 ly (n = 30) who were either carriers (T+) or noncarriers (T-) of the DISC1 translocation.

262 r CHEK2*1100delC heterozygotes compared with noncarriers, the age- and sex-adjusted hazard ratios wer

263 elated with BMI in APOE4 carriers but not in noncarriers, the following 2 groups were formed accordin

264 ps and cognitively normal APOE4 carriers and noncarriers; the sample sizes needed to detect attenuate

265 ride levels that were lower than those among noncarriers; these mutations were also associated with p

266 vival is reduced in GBA carriers compared to noncarriers; this seems to be partially independent from

267 n was performed on all mutation carriers and noncarriers to establish clinical and genetic cosegregat

268 AD51 mutation carriers were more likely than noncarriers to have a family history of ovarian cancer (

269 carriers were significantly more likely than noncarriers to have an intensification of their antiplat

270 ant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio,

271 ore cost-effective but increases exposure of noncarriers to mupirocin and the risk of resistance to m

272 profile and higher genomic instability than noncarrier tumours.

273 r CHEK2*1100delC heterozygotes compared with noncarriers was 2.08 (95% CI, 1.51 to 2.85) for breast c

274 arker changes that distinguish carriers from noncarriers was estimated using best-fitting regression

275 S between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33

276 ole blood from 43 persistent carriers and 49 noncarriers was stimulated with viable S. aureus T-helpe

277 When we compared p.P50T/AKT2 carriers to noncarriers, we found a 39.4% reduction in whole-body GU

278 cteristics between rare variant carriers and noncarriers were analyzed using univariable generalized

279 e, 0) and between APOE epsilon4 carriers and noncarriers were compared.

280 ios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression

281 A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis.

282 No differences between LypW carriers and noncarriers were observed in virus-specific CD8(+) T-cel

283 Forty-one APOE4 carriers and 41 noncarriers were prospectively recruited and consumed an

284 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy.

285 arriers of mild mutations overlapped with PD noncarriers, whereas carriers of severe mutations were c

286 d 167 prediagnosis mutation carriers and 156 noncarriers, whereas COHORT had 366 prediagnosis mutatio

287 men that was two times as high as that among noncarriers, which indicates that genetic variation in P

288 thicker left ventricular walls compared with noncarriers while its etiological fraction is limited (0

289 st risk of incident MCI for APOE varepsilon4 noncarriers who engage in mentally stimulating activitie

290 ry performance between CLU risk carriers and noncarriers who remained cognitively normal.

291 nth-old infants (23 epsilon4 carriers and 36 noncarriers), who remained asleep during the scanning se

292 de of risk reduction was similar in epsilon4 noncarriers with a high cognitive reserve indicator (HR

293 The referent group was noncarriers with adequate vitamin D status (>/=30 ng/mL)

294 PREMM5 distinguished carriers from noncarriers with an AUC of 0.81 (95% CI, 0.79 to 0.82),

295 antly worse memory scores than those of both noncarriers with high-folate and del/del carriers with n

296 ter cognitive and motor performance than did noncarriers with long disease duration, suggesting slowe

297 Of the 37 APOE4 noncarriers with minimal neuritic plaques, 16 individual

298 examine WMH differences between carriers and noncarriers with respect to EYO.

299 e-third of apolipoprotein E epsilon4 (APOE4) noncarriers with the clinical diagnosis of mild to moder

300 In this study, more than one-third of APOE4 noncarriers with the primary clinical diagnosis of mild